Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.



Orally administrated mesoporous silica capped with cucurbit[8]uril complex to combat colitis and improve intestinal homeostasis by targeting gut microbiota

Abstract

Rationale: Inflammatory bowel diseases (IBD) are still awaiting innovative treatments that can maximize the efficiency of site-specific drug release in the colon while enhancing the intestinal homeostasis. Methods: Herein, we present multilayer-coated mesoporous silica (MSs) which release payload drugs specifically in the colon tract in the presence of azoreductase produced by the gut microbiota, and simultaneously rejuvenate tryptophan metabolism of the microbiome to induce activation of the aryl hydrocarbon receptor (AHR) for increased anti-inflammatory effects. The MSs were prepared by using cucurbit[8]uril (CB[8]) as a supramolecular “handcuff” to assemble chitosan/hyaluronic acid multilayers on the periphery of a mesoporous silica core. Results: Strikingly, while MSs remained fairly stable in both acidic and neutral pH, they exhibited excellent responsiveness towards dithionite, an azo-reducing agent employed as a substitute to mimic the specific azoreductase environment in vitro. In comparison to drug in its free form, hydrocortisone-loaded MSs showed optimized accumulation of therapeutics in the colonic mucosa with minimized premature release in the upper gastrointestinal tract in in vivo imaging and biodistribution studies. The enhanced therapeutic effects of MSs were confirmed in dextran sodium sulfate-induced colitis in mice with promoted colonic epithelial barrier integrity, elevated level of AHR agonists and modulated production of inflammatory cytokines. Furthermore, 16S rRNA analysis showed that the disrupted gut homeostasis of colitic mice was partly corrected by MSs. Conclusion: This novel drug delivery system using self-assembly of tryptophan-functionalized chitosan, which was precomplexed with CB[8], and azobenzene-functionalized hyaluronic acid on the surface of mesoporous silica nanoparticles provides a synergistic gut microbiota-targeting approach for IBD therapy.

Back to tab navigation

Supplementary files

Article information


Submitted
17 Apr 2020
Accepted
21 Jun 2020
First published
23 Jun 2020

Nanoscale, 2020, Accepted Manuscript
Article type
Paper

Orally administrated mesoporous silica capped with cucurbit[8]uril complex to combat colitis and improve intestinal homeostasis by targeting gut microbiota

S. Cheng, H. Shen, S. Zhao, Y. zhang, H. xu, L. Wang, B. Di, L. Xu and C. Hu, Nanoscale, 2020, Accepted Manuscript , DOI: 10.1039/D0NR03037F

Social activity

Search articles by author

Spotlight

Advertisements